The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer
Metrics: PDF 929 views | HTML 1510 views | ?
Huan Xu1,*, Shi Fu1,*, Qi Chen1, Meng Gu1, Juan Zhou1, Chong Liu1, Yanbo Chen1, Zhong Wang1
1Department of Urology, Shanghai 9th People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China
*These authors contributed equally to this work
Zhong Wang, email: firstname.lastname@example.org
Yanbo Chen, email: email@example.com
Keywords: prostate cancer, oxytocin, APPL1, metabolism, proliferation
Received: November 07, 2016 Accepted: March 01, 2017 Published: March 10, 2017
Purpose: To measure the level of oxytocin in serum and prostate cancer (PCa) tissue and study its effect on the proliferation of PCa cells.
Results: Oxytocin level in serum was significantly increased in PCa patients compared with the no-carcinoma individuals. Additionally, the levels of oxytocin and its receptor were also elevated in the PCa tissue. However, no significant difference existed among the PCa of various Gleason grades. Western blot analysis confirmed the previous results and revealed an increased expression level of APPL1.
Materials and methods: The level of oxytocin in serum was measured by ELISA analysis. The expression of oxytocin and its receptor in prostate was analyzed by immunohistochemistry. The proliferation and apoptosis of PCa cells were assessed by the Cell Counting Kit 8 (CCK8) assay, cell cycle analysis and caspase3 activity analysis, respectively. Western blot analysis was used for the detection of PCNA, Caspase3 and APPL1 protein levels.
Conclusions: Serum and prostatic oxytocin levels are increased in the PCa subjects. Serum oxytocin level may be a biomarker for PCa in the future. Oxytocin increases PCa growth and APPL1 expression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.